HOME >> BIOLOGY >> NEWS
Pacemaker therapy halves heart failure deaths

Using specialized pacemakers to recharge the weakened hearts of heart failure patients can halve the death rate from the disease and reduce hospitalizations by nearly a third, a Johns Hopkins study has found.

Results of the study, which analyzed clinical trials of pacemaker therapy for heart failure involving a total of 1,634 patients, are published in the Feb. 12 issue of The Journal of the American Medical Association.

"The devices range in cost from $20,000 to $50,000," says lead author David J. Bradley, M.D., Ph.D., a cardiology fellow. "These specialized pacemakers have been known to improve the quality of life for heart failure patients, but whether they also save lives had been unclear."

Heart failure accounts for more than 700,000 hospitalizations among Medicare beneficiaries every year, Bradley says. In the year 2000, hospitalization charges amounted to $14 billion. Half of deaths among these patients are caused by progressive cardiac dysfunction, which pacemakers help correct by stimulating the heart muscle to contract, pumping blood to the body.

Heart failure, which affects nearly 5 million people in the United States, is a condition in which the heart can't pump enough blood to the body's other organs. This can result from assorted problems including heart attack, high blood pressure or heart valve disease. The "failing" heart keeps working but not as efficiently as it should. People with heart failure can't exert themselves because they become short of breath and tired.

Advances in technology have increased the number of people diagnosed with heart failure each year, says senior author Neil R. Powe, M.D., M.P.H., director of Johns Hopkins' Welch Center for Prevention, Epidemiology and Clinical Research. About 550,000 new patients are diagnosed annually, he says.

"We can often save heart attack patients with drugs like thrombolytics or with angioplasty, but they survive with weakened hearts, and ofte
'"/>

Contact: John Lazarou
jlazaro1@jhmi.edu
410-502-8902
Johns Hopkins Medical Institutions
11-Feb-2003


Page: 1 2

Related biology news :

1. Researchers Discover Novel Gene Family Responsible For Pacemaker Activity In Brain And Heart
2. Protecting the Beat Of Life: Test Center Studies Interaction Between Pacemakers & Electronic Article Surveillance Systems
3. Evaluation Of The Two Types Of Cardiac Pacemakers Indicates Only Modest Differences In Value
4. Targeted therapy knocks out pediatric brain cancer in mice
5. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
6. Columbia research to examine gene influence on severity of peridontal disease, therapy response
7. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
8. The search for a kinder, gentler chemotherapy
9. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
10. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
11. Gene changes linked to increased eye pressure may have implications for glaucoma therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):
(Date:5/22/2017)... , ... May 22, 2017 , ... ... with other leaders of the Maryland Biohealth community in developing and issuing recommendations ... Top 3 U.S. BioHealth Innovation Hub by 2023. , The ...
(Date:5/21/2017)... (PRWEB) , ... May 20, 2017 , ... ... that helps avoid the lengthy trial and error process by finding the right ... It can also strengthen the doctor-patient relationship through a personalized approach to treatment. ...
(Date:5/18/2017)... ... May 18, 2017 , ... ... April 28, 2017 at the Prince Of Wales Private Hospital. The procedure was ... level C6-C7. The patient failed conservative treatments prior to undergoing surgery. , The ...
(Date:5/18/2017)... ... 17, 2017 , ... NDA Partners Chairman Carl Peck, MD , announced ... Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, has joined the ... Health, he was former Chief Operating Officer at Anaborex, Senior VP and General Manager ...
Breaking Biology Technology:
Cached News: